Free Trial

Surrozen (SRZN) Competitors

Surrozen logo
$13.60 -0.19 (-1.38%)
As of 12:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SRZN vs. FULC, IMAB, CYRX, SLDB, OCGN, CGEM, DRUG, FDMT, NGNE, and DBVT

Should you be buying Surrozen stock or one of its competitors? The main competitors of Surrozen include Fulcrum Therapeutics (FULC), I-Mab (IMAB), CryoPort (CYRX), Solid Biosciences (SLDB), Ocugen (OCGN), Cullinan Therapeutics (CGEM), Bright Minds Biosciences (DRUG), 4D Molecular Therapeutics (FDMT), Neurogene (NGNE), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry.

Surrozen vs. Its Competitors

Fulcrum Therapeutics (NASDAQ:FULC) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 7.0% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 45.2% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Fulcrum Therapeutics has a beta of 2.93, suggesting that its stock price is 193% more volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.

Fulcrum Therapeutics currently has a consensus price target of $11.20, indicating a potential upside of 16.28%. Surrozen has a consensus price target of $38.50, indicating a potential upside of 183.09%. Given Surrozen's higher probable upside, analysts clearly believe Surrozen is more favorable than Fulcrum Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fulcrum Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Surrozen
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Fulcrum Therapeutics had 8 more articles in the media than Surrozen. MarketBeat recorded 9 mentions for Fulcrum Therapeutics and 1 mentions for Surrozen. Surrozen's average media sentiment score of 1.05 beat Fulcrum Therapeutics' score of 0.44 indicating that Surrozen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fulcrum Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Surrozen
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Fulcrum Therapeutics has higher revenue and earnings than Surrozen. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulcrum Therapeutics$80M6.51-$9.73M-$1.22-7.90
Surrozen$12.62M9.23-$63.56M-$14.42-0.94

Fulcrum Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -274.42%. Fulcrum Therapeutics' return on equity of -31.05% beat Surrozen's return on equity.

Company Net Margins Return on Equity Return on Assets
Fulcrum TherapeuticsN/A -31.05% -28.96%
Surrozen -274.42%-545.43%-64.40%

Summary

Fulcrum Therapeutics beats Surrozen on 12 of the 17 factors compared between the two stocks.

Get Surrozen News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRZN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRZN vs. The Competition

MetricSurrozenMED IndustryMedical SectorNASDAQ Exchange
Market Cap$116.55M$2.65B$6.16B$10.63B
Dividend YieldN/A57.79%5.72%4.85%
P/E Ratio-0.9424.1129.4927.39
Price / Sales9.23589.35494.36189.83
Price / CashN/A27.2425.8230.35
Price / Book-2.085.4212.466.70
Net Income-$63.56M$33.06M$3.32B$276.34M
7 Day Performance-0.29%2.79%2.21%0.29%
1 Month Performance10.75%12.09%9.00%4.13%
1 Year Performance44.99%-0.96%63.72%33.94%

Surrozen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRZN
Surrozen
2.226 of 5 stars
$13.60
-1.4%
$38.50
+183.1%
+36.2%$116.55M$12.62M-0.9480Positive News
Gap Down
FULC
Fulcrum Therapeutics
2.5146 of 5 stars
$8.69
-0.7%
$9.60
+10.5%
+162.7%$473.30M$80M-7.12100Analyst Forecast
IMAB
I-Mab
2.9318 of 5 stars
$6.06
+4.7%
$7.33
+21.0%
+252.7%$472.81M$3.89M0.00380Analyst Downgrade
Gap Down
CYRX
CryoPort
3.4662 of 5 stars
$9.32
-0.9%
$12.56
+34.7%
+39.6%$470.63M$228.38M7.011,186
SLDB
Solid Biosciences
2.8428 of 5 stars
$6.23
+3.7%
$15.00
+140.8%
-6.8%$467.99M$8.09M-2.23100Analyst Downgrade
OCGN
Ocugen
1.1012 of 5 stars
$1.63
+1.9%
$6.00
+268.1%
+72.3%$467.69M$4.05M-8.1580
CGEM
Cullinan Therapeutics
3.4276 of 5 stars
$7.74
-1.1%
$26.00
+235.9%
-49.0%$462.55MN/A-2.4030
DRUG
Bright Minds Biosciences
3.0485 of 5 stars
$68.37
+5.2%
$81.00
+18.5%
+39.2%$457.65MN/A-73.52N/APositive News
FDMT
4D Molecular Therapeutics
2.757 of 5 stars
$9.97
+3.1%
$30.40
+204.9%
+32.1%$451.61M$40K-2.82120News Coverage
Analyst Forecast
NGNE
Neurogene
1.8227 of 5 stars
$33.20
+5.0%
$46.17
+39.1%
-40.9%$451.28M$930K-7.7090
DBVT
DBV Technologies
1.2886 of 5 stars
$15.65
-4.7%
$14.75
-5.8%
+362.6%$449.96M$4.15M-3.2880Positive News

Related Companies and Tools


This page (NASDAQ:SRZN) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners